

Special Issue

Biological Evaluation and Biomedical Application of Nanoparticles-Based Formulations

Message from the Guest Editors

Nanoparticles-based pharmaceutical dosage forms became one of the major research areas in pharmaceutical research. The choice of lipid nanoparticles as a carrier for siRNA and mRNA in a recent marketed drug and vaccines highlights the advancements in production, characterization, and biological evaluation of nanoparticles for therapeutic and diagnostic applications. This Special Issue will therefore consider some of the recent studies in the field of biological evaluation of nanomedicines. It is open for studies that describe and discuss an original approach, technical advancement, or new models regarding nanoparticles' evaluation and models validation. Reviews discussing this topic with critical analysis and expert opinion are welcome. This Special Issue aims to provide a comprehensive overview of nanoparticles' biological evaluation using optimized protocols and experimental models.

Guest Editors

Dr. Khair Alhareth

Chemical and Biological Technologies for Health Group (UTCBS),
CNRS, INSERM, Université de Paris, F-75006 Paris, France

Prof. Dr. Karine Andrieux

Chemical and Biological Technologies for Health Group (UTCBS),
CNRS, INSERM, Université de Paris, F-75006 Paris, France

Deadline for manuscript submissions

closed (10 July 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/78584

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).